CRTX logo

Cortexyme (CRTX) Stock

Profile

Full Name:

Cortexyme, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 May 2019

Indexes:

Not included

Description:

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with CRTX included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of Cortexyme?
  • What is the ticker symbol for Cortexyme?
  • Does Cortexyme pay dividends?
  • What sector is Cortexyme in?
  • What industry is Cortexyme in?
  • What country is Cortexyme based in?
  • When did Cortexyme go public?
  • Is Cortexyme in the S&P 500?
  • Is Cortexyme in the NASDAQ 100?
  • Is Cortexyme in the Dow Jones?
  • When does Cortexyme report earnings?

What is the primary business of Cortexyme?

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

What is the ticker symbol for Cortexyme?

The ticker symbol for Cortexyme is NASDAQ:CRTX

Does Cortexyme pay dividends?

No, Cortexyme does not pay dividends

What sector is Cortexyme in?

Cortexyme is in the Healthcare sector

What industry is Cortexyme in?

Cortexyme is in the Biotechnology industry

What country is Cortexyme based in?

Cortexyme is headquartered in United States

When did Cortexyme go public?

Cortexyme's initial public offering (IPO) was on 09 May 2019

Is Cortexyme in the S&P 500?

No, Cortexyme is not included in the S&P 500 index

Is Cortexyme in the NASDAQ 100?

No, Cortexyme is not included in the NASDAQ 100 index

Is Cortexyme in the Dow Jones?

No, Cortexyme is not included in the Dow Jones index

When does Cortexyme report earnings?

The date for Cortexyme's next earnings report has not been announced yet